Audio Journal of Oncology in Advance – May 1st, 2007 – reporting from: American Association for Cancer Research 14-18 April, 2007 Los Angeles
Fritz Schröder
Opportunistic Prostate Screening May Not Save Lives!
REFERENCE: AACR 2007, Los Angeles
FRITZ SCHRÖDER, Erasmus University, Rotterdam
Though elective screening appears to have reduced the number of patients who die from prostate cancer in the United States, this has yet to be proven. A large European study is currently seeking to settle the matter, and one of the investigators, Fritz Schröder took part in a debate at the AACR entitled: Opportunistic Screening for Prostate Cancer: The Up and Down Sides of PSA Testing. Peter Goodwin talked with him about the dilemmas involved with prostate screening.
FRITZ SCHRÖDER, Erasmus University, Rotterdam
Though elective screening appears to have reduced the number of patients who die from prostate cancer in the United States, this has yet to be proven. A large European study is currently seeking to settle the matter, and one of the investigators, Fritz Schröder took part in a debate at the AACR entitled: Opportunistic Screening for Prostate Cancer: The Up and Down Sides of PSA Testing. Peter Goodwin talked with him about the dilemmas involved with prostate screening.
Peter Scardino
Debate on PSA Screening
REFERENCE: AACR 2007, Los Angeles
PETER SCARDINO, Memorial Sloan-Kettering Cancer Center, New York
The benefits of prostate cancer screening programs were questioned in a debate at the AACR conference in Los Angeles. Because the link between early detection and mortality is not simple, treatment risks could mean there is still an argument for watchful waiting in many patients. Peter Goodwin talked with Peter Scardino about the problems clinicians are facing in the age of the PSA test.
PETER SCARDINO, Memorial Sloan-Kettering Cancer Center, New York
The benefits of prostate cancer screening programs were questioned in a debate at the AACR conference in Los Angeles. Because the link between early detection and mortality is not simple, treatment risks could mean there is still an argument for watchful waiting in many patients. Peter Goodwin talked with Peter Scardino about the problems clinicians are facing in the age of the PSA test.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
